Loading people...
Glenn Rockman is a New York-based Managing Partner at Adjuvant Capital, a life sciences investment firm he co-founded in 2018 to finance medical innovations for historically overlooked diseases. He previously served as a Managing Partner at the Global Health Investment Fund, a venture vehicle sponsored by the Bill & Melinda Gates Foundation, and spent over a decade as an Executive Director in Social Finance at J.P. Morgan. At Adjuvant Capital, Rockman oversees a $300 million flagship fund dedicated to global public health, vaccine technology, and diagnostics in emerging markets. His investment portfolio includes board seats at VitriVax, Univercells, and Codagenix, alongside past investments such as Themis, which was acquired by Merck in 2020. He holds an AB in public policy from Princeton University and serves as Vice Chair of WaterEquity, focusing on water and sanitation investments.
Glenn Rockman serves as a Managing Partner at Adjuvant Capital, a pioneering venture capital firm dedicated to advancing global health technologies. In this pivotal role, Mr. Rockman is instrumental in shaping Adjuvant Capital's investment strategy, focusing on companies that develop innovative solutions for some of the world's most pressing health challenges. His leadership helps guide the firm's mission to invest in and nurture enterprises capable of delivering significant health impact alongside compelling financial returns.
Adjuvant Capital, under Mr. Rockman's guidance, targets investments across a spectrum of global health areas. This includes a strong emphasis on vaccines, therapeutics, diagnostics, and other health innovations designed to address infectious diseases, maternal and child health issues, and non-communicable diseases prevalent in low- and middle-income countries. The firm's unique model, supported by organizations like the Bill & Melinda Gates Foundation and the International Finance Corporation, allows it to back promising technologies that might otherwise struggle to attract traditional venture funding due to market complexities or long development timelines.
Mr. Rockman's extensive career background provides a robust foundation for his work at Adjuvant Capital. Prior to co-founding Adjuvant Capital, he held a significant position as a Director at the Bill & Melinda Gates Foundation, where he led investments in global health. This experience provided him with deep insights into the specific needs and opportunities within the global health landscape. Before his impactful tenure at the Gates Foundation, Mr. Rockman honed his financial expertise in investment banking at Goldman Sachs and in private equity. This diverse professional journey has equipped him with a unique blend of financial acumen and a profound understanding of the complexities and potential of global health innovation.
His strategic vision helps identify and support companies that are not only scientifically sound but also possess the potential for broad accessibility and affordability in the markets that need them most. Glenn Rockman's commitment to leveraging capital for positive global change underscores Adjuvant Capital's role as a vital player in the ecosystem of global health venture capital, driving progress towards a healthier, more equitable world.
Glenn Rockman is a Managing Partner at Adjuvant Capital, a venture capital firm focused on global health technologies. He is known for his leadership in investing in innovative solutions like vaccines, therapeutics, and diagnostics for underserved populations worldwide.
Glenn Rockman, through Adjuvant Capital, invests in global health technologies. This includes vaccines, therapeutics, diagnostics, and other health innovations addressing infectious diseases, maternal and child health, and non-communicable diseases, particularly in low- and middle-income countries.
Glenn Rockman works as a Managing Partner at Adjuvant Capital, a global health venture capital firm.
